Insmed Incorporated (NASDAQ: INSM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
98.75
+0.30+0.30%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -5.75 | Insider Own | 1.00% | Shs Outstand | 216.75M | Perf Week | -5.17% |
| Market Cap | 21.40B | Forward P/E | - | EPS next Y | 0.33 | Insider Trans | -17.95% | Shs Float | 198.42M | Perf Month | -11.47% |
| Enterprise Value | 20.93B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 5.86% | Perf Quarter | -29.47% |
| Income | -1.18B | P/S | 26.13 | EPS this Y | 54.60% | Inst Trans | - | Short Ratio | 3.09 | Perf Half Y | -35.87% |
| Sales | 819.00M | P/B | 30.36 | EPS next Y | 112.75% | ROA | -57.02% | Short Interest | 11.62M | Perf YTD | -43.26% |
| Book/sh | 3.25 | P/C | 17.49 | EPS next 5Y | - | ROE | -130.11% | 52W High | 212.73 -53.58% | Perf Year | -9.15% |
| Cash/sh | 5.65 | P/FCF | - | EPS past 3/5Y | - | ROIC | -65.28% | 52W Low | 90.39 9.25% | Perf 3Y | 362.53% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 35.24% 29.88% | Gross Margin | 81.56% | Volatility | 3.27% 3.55% | Perf 5Y | 314.74% |
| Dividend TTM | - | EV/Sales | 25.55 | EPS Y/Y TTM | -3.23% | Oper. Margin | -137.74% | ATR (14) | 3.93 | Perf 10Y | 792.05% |
| Dividend Ex-Date | - | Quick Ratio | 4.10 | Sales Y/Y TTM | 125.00% | Profit Margin | -144.44% | RSI (14) | 34.79 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.47 | EPS Q/Q | 46.48% | SMA20 | -7.76% | Beta | 0.78 | Target Price | 199.82 |
| Payout | 0.00% | Debt/Eq | 1.04 | Sales Q/Q | 229.03% | SMA50 | -5.48% | Rel Volume | 1.09 | Prev Close | 98.45 |
| Employees | 1,664 | LT Debt/Eq | 1.01 | Earnings | Aug 06 | SMA200 | -32.81% | Avg Volume | 3.95M | Price | 98.75 |
| IPO Date | Jun 01, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.11% 1.71% | Net Debt/EBITDA | -0.15 | Volume | 4,290,652 | Change | 0.30% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | Cantor Fitzgerald | Overweight | $230 → $235 |
| Jul-20-26 | Initiated | BMO Capital | Outperform | $192 |
| Jul-20-26 | Reiterated | H.C. Wainwright | Buy | $245 → $220 |
| Jul-15-26 | Reiterated | Wells Fargo | Overweight | $160 → $161 |
| Jun-16-26 | Reiterated | Mizuho Securities | Outperform | $202 → $192 |
| May-08-26 | Reiterated | Guggenheim | Buy | $230 → $226 |
| May-08-26 | Reiterated | Wells Fargo | Overweight | $208 → $160 |
| Apr-16-26 | Reiterated | Guggenheim | Buy | $227 → $230 |
| Apr-14-26 | Reiterated | RBC Capital | Outperform | $200 → $216 |
| Apr-10-26 | Initiated | Raymond James | Outperform | $200 |
Latest News
Jul-29-26
04:05AM
Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova Scotiadefenseworld.net
Jul-27-26
Jul-23-26
Jul-23-2607:00AM
Jul-22-26
Jul-21-26
07:58AM
07:41AM
Jul-20-26
Jul-20-2611:36AM
Jul-19-26
Jul-16-26
Jul-16-2604:26PM
02:32PM
11:05AM
07:00AM
Jul-14-26
Company
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 819 | 606 | 364 | 305 | 245 | 188 | 164 | 136 | 10 | |
| Cost of Goods Sold Incl. D&A | 151 | 125 | 86 | 66 | 55 | 44 | 40 | 24 | 2 | |
| Gross Profit | 668 | 482 | 278 | 240 | 190 | 144 | 125 | 112 | 7 | |
| Selling, General and Administrative Excl. Other | 800 | 701 | 461 | 345 | 266 | 234 | 204 | 211 | 168 | |
| Research and Development | 827 | 771 | 598 | 571 | 398 | 273 | 181 | 132 | 145 | |
| Other Operating Expense | 170 | 186 | 97 | 33 | -16 | 12 | 5 | 5 | 2 | |
| Operating Income | -1,129 | -1,177 | -878 | -710 | -457 | -375 | -265 | -235 | -307 | |
| Interest Expense | 82 | 84 | 85 | 82 | 26 | 40 | 30 | 28 | 25 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 33 | -11 | 53 | 44 | 4 | -21 | 2 | 9 | 9 | |
| Net Income Before Taxes | -1,178 | -1,272 | -910 | -747 | -480 | -436 | -293 | -254 | -324 | |
| Income Taxes | 5 | 5 | 4 | 3 | 1 | -2 | 1 | 1 | 0 | |
| Consolidated Net Income | -1,184 | -1,277 | -914 | -750 | -482 | -435 | -294 | -254 | -324 | |
| Net Income From Continuing Operations | -1,184 | -1,277 | -914 | -750 | -482 | -435 | -294 | -254 | -324 | |
| Net Income | -1,184 | -1,277 | -914 | -750 | -482 | -435 | -294 | -254 | -324 | |
| EPS (Recurring) | -5.75 | -6.41 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | |
| EPS (Basic, Before Extraordinaries) | -5.75 | -6.41 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | |
| EPS (Diluted) | -5.75 | -6.41 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | |
| EBITDA | -1,081 | -1,172 | -819 | -660 | -447 | -384 | -250 | -217 | -295 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 25.92 | 61.46 | 31.11 | 14.22 | 10.03 | 16.23 | 19.89 | 14.92 | 101.02 | |
| Gross Margin | 81.56 | 79.54 | 76.37 | 78.69 | 77.55 | 76.60 | 76.22 | 82.35 | 70.00 | |
| Operating Margin | -137.85 | -194.22 | -241.21 | -232.79 | -186.53 | -199.47 | -161.59 | -172.79 | -3,070.00 | |
| Net Margin | -144.57 | -210.73 | -251.10 | -245.90 | -196.73 | -231.38 | -179.27 | -186.76 | -3,240.00 | |
| Shares Outstanding | 215 | 214 | 164 | 140 | 123 | 112 | 98 | 85 | 77 | |
| Market Capitalization | 21,231 | 37,245 | 11,323 | 4,339 | 2,458 | 3,051 | 3,262 | 2,030 | 1,010 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO | Jul 23 '26 | Sale | 106.06 | 10,700 | 1,134,890 | 259,058 | Jul 24 |
| Lewis William | Chair and CEO | Jul 23 '26 | Option Exercise | 24.94 | 10,700 | 266,870 | 269,758 | Jul 24 |
| Lewis William | Chair and CEO | Jul 09 '26 | Option Exercise | 24.94 | 10,699 | 266,839 | 269,757 | Jul 10 |
| Lewis William | Chair and CEO | Jul 09 '26 | Sale | 117.40 | 10,699 | 1,256,085 | 259,058 | Jul 10 |
| Flammer Martina M.D. | Chief Medical Officer | Jul 06 '26 | Option Exercise | 25.80 | 12,302 | 317,445 | 72,788 | Jul 08 |
| Flammer Martina M.D. | Chief Medical Officer | Jul 06 '26 | Sale | 109.98 | 12,302 | 1,352,932 | 60,486 | Jul 08 |
| Lewis William | Chair and CEO | Jun 25 '26 | Option Exercise | 24.94 | 21,398 | 533,679 | 280,315 | Jun 26 |
| Lewis William | Chair and CEO | Jun 25 '26 | Sale | 103.32 | 21,398 | 2,210,763 | 258,917 | Jun 26 |
| Smith Michael Alexander | Chief Legal Officer | Jun 22 '26 | Sale | 95.82 | 1,806 | 173,051 | 37,648 | Jun 24 |
| Lewis William | Chair and CEO | Jun 08 '26 | Sale | 94.03 | 6,515 | 612,605 | 258,917 | Jun 10 |
| Flammer Martina M.D. | Chief Medical Officer | Jun 05 '26 | Sale | 103.78 | 1,858 | 192,823 | 60,486 | Jun 05 |
| Adsett Roger | Chief Operating Officer | Jun 03 '26 | Sale | 102.27 | 2,370 | 242,380 | 98,603 | Jun 05 |
| Bonstein Sara | Chief Financial Officer | Jun 03 '26 | Sale | 102.27 | 2,404 | 245,857 | 69,082 | Jun 05 |
| Smith Michael Alexander | Chief Legal Officer | Jun 03 '26 | Sale | 102.27 | 2,159 | 220,801 | 39,454 | Jun 05 |
| Lewis William | Chair and CEO | Jun 03 '26 | Sale | 102.27 | 7,605 | 777,763 | 265,432 | Jun 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.